Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors

Ana P. S. Silva, Priscila V. Coelho, Maristella Anazetti, and Patricia U. Simioni

Department of Biomedical Science, Faculty of Americana, Americana, SP, Brazil; Department of Health Science, Faculty DeVry Metrocamp, Campinas, SP, Brazil; Department of Genetics, Evolution and Bioagents, Institute of Biology, University of Campinas (UNICAMP), Campinas, SP, Brazil; Department of Biochemistry and Microbiology, Institute of Biosciences, Universidade Estadual Paulista, UNESP, Rio Claro, SP, Brazil

ABSTRACT

The usual treatments for patients with non-small-cell lung cancer (NSCLC), such as advanced lung adenocarcinoma, are unspecific and aggressive, and include lung resection, radiotherapy and chemotherapy. Recently, treatment with monoclonal antibodies and biological inhibitors has emerged as an effective alternative, generating effective results with few side effects. In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and 4 of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab. Also, biological inhibitors are attractive tools for biological applications. Among the approved inhibitors are crizotinib, erlotinib, afatinib and gefitinib, and side effects are usually mild to intense. Nevertheless, biological molecule treatments are under development, and several new monoclonal antibodies and biological inhibitors are in trial to treat NSCLC. Also under trial study are as follows: anti-epidermal growth factor receptor (EGFR) antibodies (nimotuzumab and ficlatuzumab), anti-IGF 1 receptor (IGF-1R) monoclonal antibody (figitumumab), anti-NR-LU-10 monoclonal antibody (nofetumomab) as well as antibodies directly affecting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) molecule (ipilimumab and tremelimumab), to receptor activator of nuclear factor-kappa B ligand (RANKL) (denosumab) or to polymerase enzyme (veliparib and olaparib). Among new inhibitors under investigation are poly-ADP ribose polymerase (PARP) inhibitors (veliparib and olaparib) and phosphatidylinositol 3-kinase (PI3K) inhibitor (buparlisib). However, the success of immunotherapies still requires extensive research and additional controlled trials to evaluate the long-term benefits and side effects.

Introduction

Lung tumors are responsible for a large percentage of mortality in the world population. Bronchial carcinoma, also known as bronchial or lung tumor is the most common malignant tumor of the lower respiratory tract. This tumor is classified into 3 main types: non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC) and lung carcinoid tumors. Squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma are subtypes of NSCLC. The main symptoms of NSCLC include cough, sputum streaked with blood, pain, voice change, worsening shortness of breath, and pneumonia or bronchitis. Bronchorrhea is a known characteristic of these tumors; however, it is relatively uncommon and appears only in the advanced stages of the disease.1-3 Pulmonary carcinoma, mainly adenocarcinoma, has a multifactorial profile and could be related to gene mutations, mainly in epidermal growth factor receptor (EGFR) and rearrangements of the anaplastic lymphoma kinase (ALK) genes. Likewise, human epidermal growth factor receptor 2 (HER2), Kirsten rat sarcoma viral oncogene homolog (KRAS), erythropoietin-producing hepatoma (EPH), rat sarcoma gene (RAS), mitogen-activated protein kinase (MAPK), V raf murine sarcoma viral oncogene homolog B1 (BRAF), phosphatidylinositol-4,5-bisphosphate3-kinase, catalytic subunit α isoform (PIK3CA), c-mesenchymal-epithelial transition (c-MET), fibroblast growth factor receptor (FGFR), discoidin domain receptor 2 (DDR2), phosphatase and tensin homolog (PTEN), protein kinase B (PKB), also known as serine/threonine-nine-specific protein kinase (AKT), and reactive oxygen species 1 (ROS1) genes are possible targets under study in the development of effective therapies for lung carcinomas and specifically to adenocarcinoma.4-9 A selection of these will be further discussed in this review.

Target therapies with biological molecules

Conventional chemotherapy and/or radiation treatments often fail to eliminate neoplastic cells. One of the reasons is that the required doses for tumor elimination are generally so high that normal tissues suffer irreversible damage due to toxicity.10,11 Because of this, immunotherapy, also called biologic therapy or biotherapy, is a possible option. These targeted therapies involve immune-based treatments with the intent to control...
tumor growth. New clinical trials using target therapies are underway and test proteins such as biological inhibitors and monoclonal antibodies, cells, vaccines and genetic treatments, among others.12-21

Biological molecules approved to treat NSCLC, and specifically adenocarcinoma, include monoclonal antibodies, such as cetuximab, bevacizumab, nivolumab, pembrolizumab (Table 1), and protein kinase inhibitors, such as erlotinib, gefitinib, crizotinib and afatinib (Table 2). Cetuximab and bevacizumab are monoclonal antibodies of EGFR and VEGF, respectively. Nivolumab and pembrolizumab are driven to programmed cell death ligand 1 (PD-L1) molecule. Crizotinib is a kinase inhibitor that has been shown to be effective in treating tumors involving ALK alterations, while gefitinib, erlotinib, and afatinib are applied to patients with tumors related to mutations in EGFR.5,22-27

Other relevant molecules are in trial and attempt to regulate immune response and will also be presented here. Among them are anti-epidermal growth factor receptor (EGFR) antibodies (nimotuzumab and ficlatuzumab), anti-insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody (figitumumab) and anti NR-LU-10 monoclonal antibody (nofetumab). Besides these listed, important new monoclonal antibodies are under development in order to block the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) molecule (ipilimumab and tremelimumab), to bind with the receptor activator of nuclear factor-kappa b ligand (RANKL) (denosumab) or to inhibit polymerase enzyme (VELiparib and Olaparib).28-37 Among new promising inhibitors under investigation are poly ADP ribose polymerase (PARP) inhibitors, such as veliparib and olaparib38-40 and phosphatidylinositol 3-kinase (PI3K) inhibitor such as buparlisib.41

Approved monoclonal antibodies for NSCLC

Anti-epidermal growth factor receptor (EGFR) antibodies

Anti-EGFR monoclonal antibodies bind to the extracellular domain of EGFR.42 EGFR family consists of 4 receptor of tyrosine kinases (ErbB1-4) that are frequently overexpressed in tumors. Ligand binding with the receptor allows receptor dimerization as well as autophosphorylation of tyrosine residues in the tail of the receptors. It provides specific docking sites for cytoplasmic proteins containing Src homology 2 and phosphotyrosine-binding domains. These proteins bind to specific phosphotyrosine residues and initiate intracellular signaling along several pathways.43 Also, EGFR expression is considered as a predictor of survival.44

Cetuximab. Cetuximab is a monoclonal antibody which targets the epidermal growth factor receptor (EGFR), found in 80%-85% of NSCLC patients.45-50 In patients with advanced lung cancer, cetuximab can be combined with conventional chemotherapy as part of treatment. Previous studies showed an increase in survival rates in clinical trials using this treatment combined with chemotherapy.51-54 Presently, there are promising studies using cetuximab in combination with other drugs, such as cisplatin and docetaxel, as neoadjuvant treatment of early-stage NSCLC.55 Although it is a rare, severe allergic reactions during the first infusion can lead to respiratory reactions and elevated blood pressure. In addition, some patients develop skin alterations, such as rashes, acne and infections. Other side effects may include fatigue, headache, fever and diarrhea.46-50

Anti-vascular endothelial growth factor antibody (VEGF) antibodies

Vascular endothelial growth factor antibody (VEGF) promotes tumor growth through enhanced endothelial cell proliferation and survival, increased migration and invasion of endothelial cells, increased permeability of vessels, as well as enhanced chemotaxis and homing of bone marrow derived vascular precursor cells. VEGFs signal through 3 tyrosine kinase receptors (VEGFR-1, VEGFR-2 and VEGFR-3) predominantly expressed by endothelial cells.56,57 VEGF receptor 2 and 3 (VEGF/R2/R3) lead to activation of the VEGF pathway. It has been shown recently that when ligand binds with VEGFR, the receptor complex would be internalized.58

Bevacizumab. Bevacizumab is an anti-VEGF humanized monoclonal able to reduce tumor expansion by controlling abnormal growth of blood vessels around the tumor. It is the first approved agent against tumor angiogenesis. It was approved by the FDA in 2004 as a first-line treatment in metastatized colorectal cancer, when used in combination with chemotherapy.59-65 Furthermore, VEGF is linked to intraocular neovascularization in diabetic retinopathy and macular degeneration associated with age. It has been proven that the expression of HER-1/EGFR and VEGF molecules in NSCLC is associated with poor prognosis. Thus, molecules have direct effects on tumor cells, and can be combined with drugs, resulting in an additional clinical benefit in the treatment of

Table 1. Approved monoclonal antibodies to non-small-cell lung cancer: immunotherapeutic molecules in use, mechanisms of action and side effects.

| Related Molecule | Target | Mechanism of action | Potentials adverse effects | Reference |
|------------------|--------|---------------------|---------------------------|-----------|
| Cetuximab        | EGF     | Inhibition of cell proliferation, enhanced apoptosis, and reduced angiogenesis, invasiveness and metastasis. | Rash on face and chest, diarrhea, loss of appetite and fatigue | 54-59 |
| Bevacizumab      | VEGF   | Selectively binds to VEGF and prevents interaction with its receptor. Anti-angiogenic agent, which prevents the abnormal growth of blood vessels around tumor. | High pressure, fatigue, leukocyte reduction, headache, sore mouth, loss of appetite and diarrhea | 66-74,76 |
| Nivolumab        | PD-1    | Induces programmed tumor cell death by binding PD-1 molecule | Tiredness, loss of appetite and nausea related side effects. The activity of the immune system | 42-44,77,78 |
| Pembrolizumab    | PD-1    | Induces programmed tumor cell death by binding PD-1 molecule | Body pain, chills, constipation, cough, fever, headache, loss of voice, rapid weight gain and bleeding | 45,79-81 |
advanced NSCLC. In addition, some studies indicate its use as a first-line treatment for metastasis occurring in lung adenocarcinoma. A biomarker study indicates that bevacizumab also improved tumor vasculature and blood perfusion in NSCLC patients. However, Bevacizumab can cause bleeding, which limits its use over long periods. Other severe but rare side effects include blood clots, bowel problems, heart disease, and delayed healing. Common side effects include high blood pressure, fatigue, reduction of leukocyte count, headache, mouth sores, loss of appetite and diarrhea.

**Anti-programmed cell death ligand 1 (PD-1) antibodies**

The PD-1 pathway is an important regulator in the induction and maintenance of peripheral tolerance. PD-1 (CD279) is a co-inhibitory receptor expressed in T-cells, B-cells, monocytes, and natural killer T-cells, after activation. Binding of PD-L1 or PD-L2 to PD-1 inhibits T-cell receptor signaling and down-regulates the expression of anti-apoptotic molecules. PD-1 suppresses T-cells later in an immune response, primarily in peripheral tissues.

**Nivolumab.** Nivolumab is a monoclonal antibody of the IgG4 isotype, which inhibits PD-1 molecule and causes the programmed death of the tumor cells. Recently, assays have been performed to test nivolumab as a kind of maintenance therapy, primarily in peripheral tissues.

**Pembrolizumab.** Pembrolizumab is an anti-PD-1 antibody that generated good results in phase I clinical trials, and the treatment shrank tumors in 18 percent of patients with advanced NSCLC that were no longer responding to chemotherapy. Pembrolizumab was premarket-approved for the treatment of both squamous and non-squamous NSCLC. In 2015, the FDA approved pembrolizumab as a second-line treatment for patients with lung cancer. However, confirmatory trials are required to verify the benefit of pembrolizumab for patients with metastatic NSCLC. Among the more common side effects are body pain, chills, constipation, cough, fever, headache, loss of voice, rapid weight gain and bleeding.

**Approved protein kinase inhibitors**

Crizotinib, gefitinib, erlotinib, and afatinib are considered small-molecule protein kinase inhibitors, specifically tyrosine kinase inhibitors (TKI). Tyrosine kinases (TK) are enzymes that catalyze phosphorylation of select tyrosine residues in target proteins. TK are responsible for the activation of proteins through a signal transduction cascade. However, phosphorylation can be inhibited by TKI. These molecules prevent tyrosine kinase phosphorylation and the activation of signal transduction pathways through targeted action on the receptor. TKIs can operate by different mechanisms: competition with adenosine triphosphate (ATP), phosphorylation or induction of conformational change on TK. The specific response of each protein kinase inhibitor is described below.

**Anaplastic Lymphoma Kinase (ALK) inhibitors**

Anaplastic Lymphoma Kinase (ALK) is a member of the insulin receptor super-family of receptor tyrosine kinases. The inhibitors of ALK are able to block the ALK kinase activity and promote tumor reduction. About five percent of NSCLC have a mutation in ALK gene that produces an abnormal protein causing tumor growth.

**Crizotinib.** Crizotinib is a molecule approved by FDA that blocks the ALK protein. This biological molecule reduced the tumor size by about 50% to 60% of patients with alterations in the ALK protein, although most of them had been previously treated with chemotherapy. The most common side effects of the treatment are nausea, vomiting, diarrhea, constipation, bloating, fatigue, edema and eye problems. Some side effects can be serious, such as decreased leukocyte count and lung and heart alterations.

Recent studies comparing crizotinib and chemotherapy showed that this molecule generated a...
reduction in symptoms on ALK-positive nonsquamous NSCLC.\textsuperscript{85} Recent clinical studies showed that the association of EGFR tyrosine kinase inhibitors and crizotinib were strongly effective targeted therapies in metastatic NSCLC, mainly in lung adenocarcinoma.\textsuperscript{6,22}

EGFR-targeting tyrosine kinase inhibitors

The EGFR is a receptor found on the surface of the cells, and is a member of the epidermal growth factor family (EGF-family) of extracellular protein ligands, with diverse cellular functions, including cell proliferation, differentiation, motility, and survival. Some lung cancer cells have an altered expression of this protein. EGFR activation stimulates several intracellular signaling pathways. The MAPK pathway and the PI3K–AKT pathway play very important roles in tumorigenesis by induction of self-sufficient growth, insensitivity to antigrowth signals, as well as escape from apoptosis, sustained angiogenesis, metastasis, and tissue invasion.\textsuperscript{86–91}

Erlotinib. Erlotinib is a molecule that blocks EGFR. It is used primarily for advanced lung cancer, and may also be used in patients with mutations in the EGFR gene, frequent in 10 to 15\% of NSCLC. This inhibitor is administered orally, and side effects are usually lessor than those of conventional chemotherapeutics. The most troubling side effects are rashes, skin infections, diarrhea, loss of appetite and fatigue.\textsuperscript{45,59,92–95} It was approved by the FDA in 2010 for the treatment of advanced non-small cell lung cancer (NSCLC) and in Europe as a mono-therapy for the maintenance treatment of patients with stable disease after chemotherapy.\textsuperscript{5,25,26,45,92–98}

Gefitinib. Gefitinib is also an inhibitor of EGFR tyrosine kinase that has shown antitumor activities in NSCLC. Gefitinib also induces differentiation in acute myeloid leukemia cell lines and in patient samples lacking EGFR by an unknown mechanism.\textsuperscript{99} In 2015, gefitinib was approved by the FDA for the treatment of patients with metastatic EGFR mutation-positive NSCLC. However, the treatment is associated with the detection of EGFR exon 19 deletions or exon 21 (L858R) substitution mutations by an FDA-approved test.\textsuperscript{100,101}

Afinatinib. Although EGFR-mutant NSCLC predicts a high sensitivity to the reversible EGFR-tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, resistance to these agents remains a clinical challenge. Afatinib is a novel dual irreversible blocker of EGFR/HER2 and HER4 and inhibitor of TK. It also inhibits transphosphorylation of HER3 protein. Based on these findings, afatinib has been tested in advanced NSCLC patients, showing that the treatment with this biological molecule significantly increased progression-free survival in pretreated patients resistant to gefitinib or erlotinib.\textsuperscript{1,5,27,86–91} Afatinib is usually administered to patients with advanced NSCLC not treated with another growth blocker. Adverse effects of this inhibitor include diarrhea, rash, stomatitis, decreased appetite, bleeding, itchiness, dry skin.\textsuperscript{1,5,27,86–89}

New monoclonal antibodies under evaluation: Candidates for NSCLC treatment

Anti-IGF 1 receptor (IGF-1R) monoclonal antibodies

The membrane-bound insulin-like growth factor 1 (IGF1) receptor is a tyrosine kinase receptor that mediates the effects of IGF-1. IGF-1 is a polypeptide protein hormone similar in molecular structure to insulin. IGF-1 plays an important role in growth and has anabolic effects. The membrane-bound insulin-like growth factor 1 (IGF1) receptors play a relevant role in IGF1 signaling, acting as biomarkers for anti-IGF1R antibody.\textsuperscript{102,103} Several studies tried to identify predictive biomarkers with relevance for monitoring the efficacy of IGF1R targeted therapy.

Figitumumab. Figitumumab is a fully human anti-IGF 1 receptor (IGF-1R) monoclonal antibody. Figitumumab has a high affinity for IGF1R/IR heterodimeric receptors as well as IGF1 homodimer receptors and inhibits the IGF/IGF1R signaling axis.\textsuperscript{104,105} Combination studies mainly using NSCLC patients showed that figitumumab was promising when associated with carboplatin and paclitaxel in phase I trial and randomized phase II study. However, a phase III study of carboplatin, paclitaxel, with or without figitumumab in first-line for metastatic NSCLC was stopped in 2009.\textsuperscript{54,106,107}

Anti NR-LU-10 monoclonal antibodies. NR-LU-10 is an antipan carcinoma monoclonal antibody. This is a murine antibody that detects an antigen found in normal colons, livers, lungs, breasts, prostates, and kidneys, and in tumors of the lungs, pancreas, colon, kidney, ovaries, and breasts. The target antigen and mechanisms of action have not yet been fully characterized.\textsuperscript{108}

Nofetumomab. Nofetumomab is a Fab fragment of murine monoclonal antibody NR-LU-10, IgG2b subclass.\textsuperscript{109,110} Nofetumomab is directed against a 40 kDa antigen, glycoprotein expressed on the surface of many tumors, including NSCLC. It is usually indicated in the detection of extensive stage disease in patients with biopsy-confirmed, previously untreated, small-cell lung cancer.\textsuperscript{109,110} There is no clinical trial under development.

Anti-epidermal growth factor receptor (EGFR) antibodies

Since EGFR is a therapeutic target for NSCLC, several therapeuetic agents targeting this receptor including antibodies of this receptor. Some monoclonal antibodies, such as Nimotuzumab and fclatuzumab, have shown efficacy in combination with chemotherapy and radiotherapy.\textsuperscript{112–117}

Nimotuzumab. Nimotuzumab (h-R3) is a humanized monoclonal antibody to EGFR, which binds to this receptor and inhibits binding of EGFR to cancer cells. It has several indications, among them: head and neck cancer, nasopharyngeal carcinoma, and esophageal cancer.\textsuperscript{111,112} It is in clinical trials for several tumor types, including NSCLC, as well as colorectal, pancreatic, cervical and breast. Serious adverse events were observed mainly consisting of tremors, fever, vomiting, nausea, dry mouth, asthenia, hypertension and flushing. The typical serious dermatological toxicities
associated with other monoclonal antibodies to EGFR were observed with nimotuzumab.112-117

**Ficlatuzumab.** In recent years, several biomarkers of lung cancer have been found and recognized as possible targets for treatment of this disease; among them is the growth factor of transition/hepatocyte mesenchymal intraepithelial (c-MET / HGF). Changes in gene c-MET and MET and HGF aberrations are involved in resistance to inhibitors of the EGFR in NSCLC patients with EGFR mutations.118 Ficlatuzumab is a monoclonal antibody (IgG1) humanized and directed to HGF and is currently under study for NSCLC. Its mechanism of action is due to its high affinity and specificity for binding to the HGF receptor, thus inhibiting gene c-MET / HGF and its biological activities. The most common adverse reactions observed in immunotherapy were fatigue, peripheral edema, headache and diarrhea.118-121

**Anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibodies**
Receptor activator of nuclear factor-kappa B ligand (RANKL) is a mediator of the formation, function and survival of osteoclast. Blocking of RANKL has been demonstrated to prevent tumor-induced osteolysis and skeletal complications.122

**Denosumab.** Denosumab is a fully human anti-receptor activator of nuclear factor-kappa B ligand (RANKL) monoclonal antibody. It is a novel agent that inhibits osteoclastic-mediated bone reabsorption by binding to osteoblast-produced RANKL. Denosumab reduces the incidence of skeletal-related events in patients with bone metastases from solid tumors. It is under evaluation for patients with lung cancer, in the phase 3 trial versus zoledronic acid (ZA). In an exploratory study, denosumab was associated with increased overall survival compared with ZA, in patients with metastatic lung cancer.123,124

**Anti-Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4) monoclonal antibodies**
Cytotoxic T-Lymphocyte-Associated Antigen (CTLA-4) molecule is known to regulate T-cell proliferation in early stages of T-cell response, primarily in lymph nodes. CTLA-4 prevents the down-regulation of cytotoxic T-cells in the early stages of T-cell activation.125 Antibodies to CTLA-4 inhibit critical negative T-cell regulators, since they inhibit the costimulatory signaling for T-cells.126-128

**Ipilimumab.** Ipilimumab is a fully human monoclonal IgG1 antibody that binds with the CTLA-4 molecule. In patients with metastatic melanoma treated previously with chemotherapy, this therapy can improve the treatment with ipilimumab. The activity of ipilimumab in combination with chemotherapeutic agents such as paclitaxel and carboplatin has been evaluated in patients with advanced chemotherapy, inducing a better treatment outcome. Ipilimumab is associated with inflammatory adverse reactions resulting from increased or excessive immune activity. Possible adverse immune reactions are gastrointestinal, liver, skin, nervous system, endocrine system or other organ systems. Although most adverse immune reactions occur during the induction period, some were also reported during the onset months after the last dose of ipilimumab.28-30,32

**Tremelimumab.** Tremelimumab (CP-675,206, anti-CTLA-4) is a fully humanized monoclonal IgG2 antibody that binds with the CTLA-4 molecule, usually used for metastatic melanoma and other cancers. CTLA-4 (CD152) is a homolog of the coactivation receptor CD28.126-128 This molecule is in phase I clinical trial and associated with durvalumab. They showed tolerability and were selected for phase 3 studies, which are ongoing.34

**New biologic inhibitors under evaluation: Candidates to NSCLC treatment**

**Poly ADP ribose polymerase (PARP) inhibitors**
Poly ADP Ribose Polymerase (PARP) inhibitors block the poly ADP ribose polymerase (PARP) which is thought to repair damage to DNA. Since many tumors are dependent on PARP, this protein can be an attractive target for therapy. They act against tumors in people with hereditary BRCA1 or BRCA2 (breast cancer 1, early onset) mutations.38

**Veliparib and olaparib.** Clinical trials for lung cancer are looking for new biological therapy drugs. Because of this, Veliparib (ABT-888) and olaparib (AZD-2281) are new biological therapies under development, called a PARP inhibitors. These inhibitors are in clinical trials to be administrated after chemotherapy to delay or prevent NSCLC remission, on maintenance therapy.38-40

**Phosphatidylinositol 3-kinase (PI3K) inhibitor**
Phosphatidylinositol 3-kinase (PI3K) enzymes, are associated with PI3K/ AKT/mTOR pathway, an important signaling pathway that regulates growth control, metabolism and translation initiation. Activation of the Phosphatidylinositol 3-kinase (PI3K) signaling pathway is frequently associated with tumorigenesis in NSCLC. Phosphatidylinositol 3-kinase (PI3K) inhibitors act by inhibiting one or more PI3K enzymes.41,129-159

**Buparlisib.** Phosphatidylinositol 3-kinase (PI3K) inhibitors include buparlisib (BKM120), a pan inhibitor of PI3K and alpelisib (BYL719), a PI3Kα-selective inhibitor.41,129-139 However, buparlisib did not meet its primary objective in stage 1 clinical trial, since PI3K pathway activation were detected in NSCLC.129 To try and solve this problem, there are new studies attempting to maximize its benefits by using buparlisib and alpelisib stratification according to PI3K pathway activation status or selective enrollment of patients and chemotherapy combination.41

**Final considerations**
Immunotherapy with biological inhibitors and monoclonal antibodies are treatments recently applied to tumors, since they cause less damage to normal cells. This technology represents enormous contributions in the treatment of lung cancer. Monoclonal antibodies are highly specific and require that tumor cells express the target antigen, since they can only activate various mechanisms involved in the immune response,
such as induction of apoptosis as well as the blockage of cell growth and transcription factors.

The increased efficacy of anticancer conventional therapy through additional treatment with biological molecules against NSCLC, especially with lung adenocarcinoma, may have significant clinical implications, constituting a new approach in cancer treatment. However, the successful development of immunotherapies requires extensive research and randomized controlled trials, to detail the proper use of these molecules, and the benefits and side effects in the long term. In several cases, many important questions such as heterogeneity of stage, timing and type of administration of these molecules are still unanswered.

Abbreviations

AIS     adenocarcinoma in situ
AKT     serine/threonine-specific protein kinase
ALK     anaplastic lymphoma kinase
ATS     American Thoracic Society
BRAF    V-raf murine sarcoma viral oncogene homolog B1
BRCA    breast cancer, early onset
c-MET/HGF growth factor of transition / hepatocyte mesenchymal intraepithelial

References

[1] Yang JC-H, Hirsh V, Schuler M, Yamamoto N, O’Byrne KJ, Mok TSK, Zazulina V, Shahidi M, Lunghausen J, Massey D, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31:3342-50; PMID:23816967; http://dx.doi.org/10.1200/JCO.2012.46.1764

[2] Gardiner N, Jogai S, Wallis A. The revised lung adenocarcinoma classification—an imaging guide. J Thorac Dis 2014; 6:5537-46; PMID:25349704

[3] National Cancer Institute. SEER cancer statistics review, 1975-2011. Available online: http://seer.cancer.gov/csr/1975_2011/

[4] Cooper WA, Lam DCL, O’Toole SA, Minna JD. Molecular biology of lung cancer. J Thorac Dis 2013; 5 Suppl:5:5479-90; PMID:24163741

[5] Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer. J Clin Oncol 2013; 31:122; PMID:24574860; http://dx.doi.org/10.14133/1477-3163.123972

[6] Liu SV, Subramaniam D, Cyriac GC, Abdul-Khalique FJ, Giaconne G. Emerging protein kinase inhibitors for non-small cell lung cancer. Expert Opin Emerg Drugs 2014; 19:51-65; PMID:24354593; http://dx.doi.org/10.1517/14728214.2014.873403

[7] Arteaga CL. EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer Cell 2006; 9:421-3; PMID:16766261; http://dx.doi.org/10.1016/j.ccr.2006.05.014

[8] Sertizawa M, Koh Y, Kenmotsu H, Akamatsu H, Mori K, Abe M, Hayashi I, Taira T, et al. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multigene assays: a prospective, single-institute study. Cancer 2014; 120:1471-81; PMID:24175049; http://dx.doi.org/10.1002/cncr.29604

[9] Hirsh V. The treatment of metastatic non-small cell lung cancer in a new era of personalized medicine. Front Oncol 2015; 5:20; PMID:25692098; http://dx.doi.org/10.3389/fonc.2015.00020

[10] Herst PM, Berridge MV. Cell hierarchy, metabolic flexibility and systems approaches to cancer treatment. Curr Pharm Biotechnol 2013; 14:289-99; PMID:22201593; http://dx.doi.org/10.2174/14773163.14.289-99

[11] Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth F-W, Tonn J-C, Belka C. Therapeutic options for recurrent malignant glioma. Radiother Oncol 2011; 98:1-14; PMID:21153936

[12] Picozzi VJ, Ramanathan RK, Lowery MA, O’Neill BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, et al. (90)Y-chelating zirconium tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. Eur J Cancer 2015; 51:1857-64; PMID:26187510; http://dx.doi.org/10.1016/j.ejca.2015.06.119

[13] Wu F, Chakravarti S. Differential expression of inflammatory and fibrogenic genes and their regulation by NF-κB inhibition in a mouse model of chronic colitis. J Immunol 2007; 179:6988-7000; PMID:17982090; http://dx.doi.org/10.4049/jimmunol.179.10.6988

Disclosure of potential conflicts of interest

The authors declare that there is no conflict of interests regarding the publication of this paper.

Funding

Grant #2013/20258-2 São Paulo Research Foundation – FAPESP.

ORCID

Patricia U. Simoneti http://orcid.org/0000-0002-6951-5040
van den Heuvel MM, Verheij B, Boshuizen R, Belderbos J, Dingemans A-MC, De Ruyscher D, Laurent J, Tighe R, Haanen J, Quartino S. NHS-II-L2 combined with radiotherapy: preclinical rationale and phase 1b trial results in metastatic non-small cell lung cancer following first-line chemotherapy. J Transl Med 2015; 13:32; PMID:25622640; http://dx.doi.org/10.1186/s12967-015-0397-0

[16] Capote T, Nego M, Geller JA, Currer MA, Racadio JM, Towbin AJ, Rooney CM, Pelusio A, Moon A, et al. Phase 1 study of intratumoral Pexa-Vec (IX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther 2014; 23:602-8; PMID:25531693; http://dx.doi.org/10.1038/mt.2014.243

Kimura H, Matsu T, Ishikawa A, Nakajima T, Yoshino M, Sakairi C, costa DB, Rabin MS, Jackman DM, Johnson BE. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2012; 18:4906-14; PMID:22733536; http://dx.doi.org/10.1158/1078-0432.CCR-12-0357

[17] Yang JC-H, Shih Y-J, Su W-C, Hsia T-C, Tsai C-M, Ou S-HI, Hu C-J, Chang G-C, Ho C-L, Sequist LV, et al. A trial of initial for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LU-Lung 2): a phase 2 trial. Lancet Oncol 2012; 13:539-48; PMID:22425895

[18] Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, Targan SR, Wang HL. Blockade of cytotoxic T-lymphocyte antigen 4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immunol Immunother 2010; 10:11; PMID:20109563

[19] Rijavec E, Genova C, Barletta G, Bursafato G, Biello F, Dal Bello MG, Coco S, Truini A, Alama A, Boccardo F, et al. Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. Expert Opin Biol Ther 2014; 14:1007-17; PMID:24702205; http://dx.doi.org/10.1517/14712598.2014.907786

[20] Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An asceptical response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013; 1:365-72; PMID:24563870; http://dx.doi.org/10.1158/2326-6066.CIR-13-0115

[21] Reck M, Heigener D, Reinmuth N. Immunotherapy for small-cell lung cancer: emerging evidence. Future Oncol 2016; 12:931-43; PMID:26882955; http://dx.doi.org/10.2217/fon-2015-0012

[22] Quirk SK, Shure AK, Agrawal DK. Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. Transl Res 2015; 166:412-24; PMID:26118951; http://dx.doi.org/10.1016/j.trsl.2015.06.005

[23] Garon EB. Current perspectives in immunotherapy for non-small cell lung cancer. Semin Oncol 2015; 42 suppl 25:S1-S12; PMID:26477470; http://dx.doi.org/10.1053/j.seminoncol.2015.09.019

[24] Antonia S, Goldberg SB, Balmanoukian A, Chaite JF, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakulken I, et al. and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1 study. Lancet Oncol 2016; 17:299-308; PMID:26858122; http://dx.doi.org/10.1016/S1470-2045(15)00544-6

[25] Peters S, Antonia S, Goldberg SB, Heymach JV, Kim ES, Nakagawa K, Papadimitrakopoulos V, Mukhopadhyay P, McIntosh S, Rizvi NA. 191TIP: MYSTIC: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC. J Thorac Oncol 2016; 11:S139-40; PMID:27198327; http://dx.doi.org/10.1016/j.jtho.2015.10.001

[26] Mok T, Schmid P, Arzn O, Arrieta O, Gottfried M, Jazieh AR, Ramau R, Timcheva K, Martin C, McIntosh N. 192TIP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC. J Thorac Oncol 2016; 11:S140-1; PMID:27198329; http://dx.doi.org/10.1016/j.jtho.2015.10.001

[27] Owonikoko TKT, Zhang G, Denc X, Rossi MR, Switchenom JM, Doho GH, Chen Z, Strycho C, Christner SM, et al. (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med 2014; 3:1579-94; PMID:25212482; http://dx.doi.org/10.1002/cam4.317

[28] Tangutoori S, Baldwin P, Sridhar S. PARP inhibitors: A new era of targeted therapy. Maturitas 2015; 81:5-9; PMID:25708226; http://dx.doi.org/10.1016/j.maturitas.2015.0300-8

[29] Owonikoko T, Dahlberg S, Khan S. A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN cancer research. Lung Cancer 2015; 89(1):66-70; http://dx.doi.org/10.1016/j.lungcan.2015.04.015

[30] Owonikoko T, Zhang G, Denc X. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med 2014; 3:1579-94; PMID:25212482; http://dx.doi.org/10.1002/cam4.317

[31] Massacesi C, Di Tomaso E, Urban P, Germa C, Quadr C, Trandafir L, Aimence P, Freutal N, Dharan B, Tavorath R, et al. PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. Oncotargets Ther 2016; 9:203-10; PMID:25708226; http://dx.doi.org/10.2147/OTT.S98967

[32] Puyeo G, Mesia R, Figueras A, Lozano A, Baro M, Vazquez S, Capella G, Balart J. Cetuximab may inhibit tumor growth and angiogenesis induced by ionizing radiation: a preclinical rationale for maintenance treatment after radiotherapy. Oncologist 2010; 15:976-86; PMID:20798193; http://dx.doi.org/10.1634/theoncologist.2008-0290
A. P. S. SILVA ET AL.

[43] Scalfriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12:5268-72; PMID:17000658; http://dx.doi.org/10.1158/1078-0432.CCR-05-1554

[44] Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramalau R, Park K, de Marinis F, Eberhardt WEE, Paz-Ares L, Störlék S, et al. EGFR expression as predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13:33-42; PMID:22056021; http://dx.doi.org/10.1016/S1470-2045(11)70318-7

[45] Janjigian YY, Azzoli CG, Krug LM, Pereira LR, Rizvi NA, Pietanza MC, Kris MG, Gimsberg MS, Pao W, Miller VA, et al. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res 2011; 17:2521-7; PMID:21484303; http://dx.doi.org/10.1158/1078-0432.CCR-10-2662

[46] Jatoi A, Schild SE, Foster N, Henning GT, Dornfeld KJ, Flynn PJ, Fitch TR, Dakhil SR, Rowland KM, Stella PJ, et al. A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422). Ann Oncol 2010; 21:2040-4; PMID:20570832; http://dx.doi.org/10.1093/annonc/mdq075

[47] Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann F, Schumacher M, Jamning H, Fiegl M, Gächter A, et al. Multicenter phase II study evaluating two cycles of docetaxel, cisplatin and cetuximab as induction regimen prior to surgery in chemotherapeutically-naive patients with NSCLC Stage IB-IIIA (INNO-Study). PLoS One 2015; 10:e0125364; PMID:26020783; http://dx.doi.org/10.1371/journal.pone.0125364

[48] Ralfi S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002; 2:826-35; PMID:12415253; http://dx.doi.org/10.1038/nrc929

[49] Gibmrome MA, Leapman SB, Cotran RS, Folkman J. Tumor angiogenesis: iris neovascularization at a distance from experimental intraocular tumors. J Natl Cancer Inst 1973; 50:219-28; PMID:4692862

[50] Sullivan LA, Breken RA. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2010; 2:1675-7; PMID:2090566; http://dx.doi.org/10.4161/mabs.2.2.11360

[51] Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, et al. Phase II/I trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23:2544-55; PMID:15753462; http://dx.doi.org/10.1200/JCO.2005.02.477

[52] Becker S, Bohn P, Bouyreh-Petit A-C, Modrzejewski R, Gensanne D, Picquenot J-M, Dubray B, Vera P. Bevacizumab enhances efficiency of radiotherapy in a lung adenocarcinoma rodent model: Role of ovβ3 imaging in determining optimal window. Nucl Med Biol 2015; 42:923-30; PMID:26410810; http://dx.doi.org/10.1016/j.nucmedbio.2015.08.002

[53] Su Y-L, Rau K-M. Adding bevacizumab to chemotherapy effectively controls radioresistant brain metastases in ALK-positive lung adenocarcinoma. J Thorac Oncol 2015; 10:e21-2; PMID:25798460; http://dx.doi.org/10.1097/JTO.0000000000000449

[54] Ou G, Itasaka S, Zeng L, Shibuya K, Yi J, Harada H, Hiraoka M. Usefulness of HIF-1 imaging for determining optimal timing of combining bevacizumab and radiotherapy. Int J Radiat Oncol Biol Phys 2009; 75:463-7; PMID:19735869; http://dx.doi.org/10.1016/j.ijrobp.2009.02.083

[55] Quoix E. [Recent development of the standards of treatment of lung cancer]. Rev Prat 2007; 57:239-45; PMID:17578022

[56] Claret L, Gupta M, Han K, Joshi A, Sarapa N, He J, Powell B, Bruno R. Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab. J Clin Pharmacol 2014; 54:253-7; PMID:24122760; http://dx.doi.org/10.1177/002204801350893

[57] Kubota T, Okano Y, Sakai M, Takaoka M, Tsukuda T, Anabuki K, Kawai S, Miyamoto S, Ohnishi H, Hatakeyama N, et al. Carboplatin plus weekly paclitaxel with bevacizumab for first-line treatment of non-small cell lung cancer. Anticancer Res 2016; 36:307-12; PMID:26722058

[58] Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, Temel JS, Shaw AT, Pennell NA, Neal JW, et al. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl...
Kazandjian D, Blumenthal GM, Yuan W, He K, Keegan P, Pazdur R, FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer. Cancer Res 2016; 22:1307-12; PMID:26980062; http://dx.doi.org/10.1158/10781552-16634179; [Epub ahead of print]; PMID:26914177

Frasca F, Pandini G, Sciaccia L, Pezzino V, Squatrito S, Belfiore A, Vigneri R. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008; 114:23-37; PMID:18465356; http://dx.doi.org/10.1080/13813450801969715

Belfiore A, Pandini G, Vella V, Squatrito S, Vigneri R. Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie 1999; 81:403-7; PMID:10401676; http://dx.doi.org/10.1016/S0300-9089(98)80068-1

Kim JG, Kang MJ, Yoon Y-K, Kim H-P, Park J, Song S-H, Han S-W, Park J-W, Kang GH, Kang KW, et al. Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGFIR antibody. PLoS One 2012; 7:e33322; PMID:22438913; http://dx.doi.org/10.1371/journal.pone.0033322

Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T, Benner RJ, Sculier JP, Olszanski AJ, Jassar D, Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol 2014; 32:2059-66; PMID:24888810; http://dx.doi.org/10.1200/JCO.2013.54.4932

Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010; 28:9495-9; PMID:20975071; http://dx.doi.org/10.1200/JCO.2009.27.5040

Rossi A, Maione P, Baraschino MA, Schettino C, Saccu PC, Ferrara ML, Castaldo V, Grifeti C. The emerging role of histology in the development of novel targeted therapy in NSCLC. Lung Cancer Targets Ther 2011; 2:59; http://dx.doi.org/10.2147/LCTT.S16440

Lin S, Yan Y, Liu Y, Gao C-Z, Shan D, Li Y, Han B. Sensitisation of human lung adenocarcinoma A549 cells to radiotherapy by Nimotuzumab is associated with enhanced apoptosis and cell cycle arrest in the G2/M phase. Cell Biol Int 2015; 39:146-51; PMID:25044496; http://dx.doi.org/10.1007/s10529-013-1042-9

Choi HJ, Sohn JH, Lee CG, Shim HS, Lee I-J, Yang WI, Kwon JE, Kim SK, Park M-S, Lee JH, et al. A phase I study of nimotuzumab in combination with radiotherapy in stages IB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer 2011; 71:55-9; PMID:20451284; http://dx.doi.org/10.1016/j.lungcan.2010.04.010

Bebb G, Smith C, Ronke S, Boland W, Nicacio L, Sukhoo R, Brade J, C-MET inhibitors in the treatment of lung cancer. Curr Treat Options Oncol 2014; 15:670-82; PMID:25266653; http://dx.doi.org/10.1007/s11864-014-0313-5

Patnaik A, Weiss GI, Papadopoulos KP, Hofmeister CC, Tiberi S, Tolcher A, Isaacs R, Jornic I, Han M, Perez PU, et al. Phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 2013; 79:270-5; PMID:23261299; http://dx.doi.org/10.1016/j.lungcan.2012.11.017

D’Arcangelo M, Cappuzzo F. Focus on the potential role of ficitumumab in the treatment of non-small cell lung cancer. Biologics 2012; 28:4985-95; PMID:20975071; http://dx.doi.org/10.1200/JCO.2014.29.0021

Bonneterre D, Rohrbach K, Huang L-Y, Soriano R, Tomokota M, Blake M, Jacob AP, Dougall WC. RANK and RANKL ligand expression in primary human osteosarcoma. J Bone Oncol 2015; 4:59-68; PMID:27556008; http://dx.doi.org/10.1016/j.bjoe.2015.06.002

Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/ HGF inhibitors in oncology. Cancer Treat Rev 2013; 39:793-801; PMID:23453860; http://dx.doi.org/10.1016/j.ctrv.2013.02.001

Goździk-Spychalska J, Szyrza-Barth K, Spychalski L, Ramlau K, Wójtowicz J, Batura-Gabryel H, Ramlau R. C-MET inhibitors in the treatment of lung cancer. Curr Treat Options Oncol 2014; 15:670-82; PMID:25266653; http://dx.doi.org/10.1007/s11864-014-0313-5
Ribas A. Anti-CTLA4 antibody clinical trials in melanoma. Update Cancer Ther 2007; 2:133-9; PMID:19543441; http://dx.doi.org/10.1016/j.uct.2007.09.001

Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy JA, Bozon V, et al. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am J Ophthalmol 2007; 143:958-69; PMID:17743437; http://dx.doi.org/10.1016/j.ajo.2007.02.035

Tahini AA, Kirkwood JM. Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer. Curr Opin Mol Ther 2007; 9:505-14; PMID:17932815

Vansteenkiste JF, Canon J-L, Braud F, DeGrossi F, De Pas T, Gray JE, Su W-C, Felip E, Yoshiko H, Gridelli C, et al. Safety and efficacy of Buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer: results from the phase II BASALT-1 study. J Thorac Oncol 2015; 10:1319-27; PMID:26098748; http://dx.doi.org/10.1097/JTO.0000000000000607

James A, Blumenstein L, Glaenzel U, Jin Y, Demailly A, Jakab A, Hansen R, Hazell K, Mehta A, Trandafir L, et al. Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers. Cancer Chemother Pharmacol 2015; 76:751-60; PMID:26254025; http://dx.doi.org/10.1007/s00280-015-2842-4

Mayer IA, Abramson V, Formisano L, Balko JM, Estrada MV, Sanders M, Juric D, Solit D, Berger MF, Won H, et al. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-specific Inhibitor, with Letrozole in ER+/HER2-negative metastatic breast cancer. Clin Cancer Res 2016; pii:ppicccncanres.0134.2016; [Epub ahead of print]

Masuishi T, Muro K. Current feasibility and usefulness of molecular-targeted agent combinations for metastatic colorectal cancer. Gan To Kagaku Ryoho 2016; 43:408-12; PMID:27220786

Perez EA. Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order. Drug Resist Updat 2016; 24:13-22; PMID:26830312; http://dx.doi.org/10.1016/j.drup.2015.11.001

Mayer IA, Abramson VG, Isaikoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, et al. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2014; 32:1202-9; PMID:24663045; http://dx.doi.org/10.1200/JCO.2013.54.0518

Rodon J, Braita I, Stiu LL, De Jonge MJ, Homji N, Mills D, Di Tomaso E, Sarr C, Trandafir L, Massacci C, et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 2014; 32:670-81; PMID:24652201; http://dx.doi.org/10.1007/s10637-014-0082-9

Hyman DM, Snyder AE, Carvajal RD, Gerecitano JF, Voss MH, Ho AL, Konner J, Winkelmann JL, Stasi MA, Monson KR, et al. Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer Chemother Pharmoc 2015; 75:747-55; PMID:25672916; http://dx.doi.org/10.1007/s00280-015-2693-z

Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste JF, Van Cutsem E, Pérez-Garcia J, Statbis A, Britten CD, et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res 2015; 21:730-8; PMID:25500057; http://dx.doi.org/10.1158/1078-0432.CCR-14-1814

Ando Y, Inada-Inoue M, Mitsuma A, Yoshino T, Ohtsu A, Suenaga N, Sato M, Kakizume T, Robson M, Quadri C, et al. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci 2014; 105:347-53; PMID:24405565; http://dx.doi.org/10.1111/cas.12350

Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, Mills D, Ruquet S, Bosch A, Urruticoechea A, et al. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzambased therapy. Clin Cancer Res 2014; 20:1935-45; PMID:24470511; http://dx.doi.org/10.1158/1078-0432.CCR-13-1070